基于抗体的免疫治疗用于免疫球蛋白轻链淀粉样变性
本文综述了免疫球蛋白轻链(AL)淀粉样变性的新型抗体免疫治疗进展。AL淀粉样变性的标准治疗包括美法仑联合自体造血干细胞移植、蛋白酶体抑制剂和免疫调节剂,但患者常复发且晚期患者可能无法耐受。单克隆抗体、双特异性抗体、抗体药物偶联物和嵌合抗原受体T细胞等免疫治疗在多发性骨髓瘤中已革新治疗格局,这些新型免疫治疗药物正在AL淀粉样变性患者中进行早期评估和临床开发。
要点
- AL淀粉样变性的标准治疗包括美法仑联合自体造血干细胞移植、蛋白酶体抑制剂和免疫调节剂。
- 单克隆抗体、双特异性抗体、抗体药物偶联物和嵌合抗原受体T细胞等免疫治疗在多发性骨髓瘤中已革新治疗格局。
- 这些新型免疫治疗药物正在AL淀粉样变性患者中进行早期评估和临床开发。
核心结论
- 本综述旨在讨论目前正在开发的新型免疫治疗的作用及其在AL淀粉样变性治疗中的潜在用途。
研究设计与样本
- 本文为综述,旨在讨论新型免疫治疗在AL淀粉样变性中的开发与潜在应用。
主要发现
- AL淀粉样变性的标准治疗包括美法仑联合自体造血干细胞移植、蛋白酶体抑制剂和免疫调节剂。
- 这些治疗对肿瘤性浆细胞高度有效,但患者常复发,晚期患者可能因副作用无法耐受。
- 单克隆抗体、双特异性抗体、抗体药物偶联物和嵌合抗原受体T细胞等免疫治疗已革新多发性骨髓瘤的治疗手段。
- 这些新型免疫治疗药物正在AL淀粉样变性患者中进行早期评估和临床开发。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunoglobulin light-chain (AL) amyloidosis is a clonal plasma cell disorder characterised by production and deposition of misfolded monoclonal light chains in vital organs with potential to cause irreversible organ damage. The treatment of AL amyloidosis has evolved along the lines of multiple myeloma (MM) owing to clonal plasma cells being at the root of both disease processes. Treatment with melphalan and autologous haematopoietic cell transplantation, as well as proteasome inhibitors and immunomodulatory agents, are the standard of care for AL amyloidosis. While these treatment modalities are highly effective against the neoplastic plasma cells, patients often relapse and those with advanced disease may be unable to tolerate these treatments due to side-effects. Immunotherapy with monoclonal antibodies, bispecific antibodies, antibody-drug conjugates and chimeric antigen receptor T cells have revolutionised the treatment armamentarium for MM. These novel immunotherapy agents are in the early phases of evaluation and clinical development for patients with AL amyloidosis. The present review aims to discuss the role of novel immunotherapies currently in development and their potential for use in the treatment of AL amyloidosis.
引用
- Parrondo RD, Majeed U, Sher T, et al. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis. Br J Haematol. 2020. PMID: 32298469. doi:10.1111/bjh.16697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。